May 30, 2024 · Osimertinib is used to treat non-small cell lung cancer that is positive for an abnormal "EGFR" gene. You doctor will test you for this gene. Osimertinib is sometimes given …

Osimertinib is provided as the mesylate; the chemical formula is C 28 H 33 N 7 O 2 ·CH 4 O 3 S, and the molecular weight is 596 g/mol. The chemical name is N-(2-{2-dimethylaminoethyl …

Osimertinib mesylate is approved to treat: Non-small cell lung cancer that has an abnormal EGFR gene. It is used in adults: who have had surgery to remove the cancer, to help keep the cancer …

Feb 1, 2025 · Osimertinib is used to treat non-small cell lung cancer (NSCLC) in patients who have certain types of abnormal epidermal growth factor (EGFR) genes. This medicine is used …

Nov 8, 2023 · Osimertinib is a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M resistance …

Jun 25, 2024 · Tagrisso (osimertinib) is commonly used for treating different kinds of epidermal growth factor receptor (EGFR) mutated lung cancer. EGFR is a protein on the surface of cells …

Sep 30, 2024 · Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose tumors have certain abnormal epidermal growth factor receptor (EGFR) …

Osimertinib is metabolized to at least two pharmacologically active metabolites, AZ7550 and AZ5104, that circulate at approximately 10% of the concentration of the parent compound. …

Osimertinib is metabolized to produce at least two pharmacologically circulating metabolites, AZ5104 and AZ7550 (17,19,24). AZ7550 showed a similar potency and selectivity to …

Jan 10, 2025 · Available as osimertinib mesylate; dosage expressed in terms of osimertinib. Adults NSCLC Adjuvant Treatment of NSCLC Oral 80 mg once daily. Continue therapy for up …